52North
About 52North
52North is a medical technology company on a mission to transform emergency care for patients globally. They build innovative diagnostic and digital solutions to make emergency care safer and more effective, focusing on urgent care pathways. Founded in 2018 as a spin-out from the University of Cambridge, the company has an award-winning multidisciplinary team and is backed by leading UK and US hospital venture funds such as Meridian Health Ventures and Cedars-Sinai Intellectual Property Co. They are also supported by major cancer charities, including Macmillan Cancer Support.
Mission and Vision
Their vision is to transform emergency care worldwide by bridging the gap between cutting-edge medical innovation and patients who need it most. Their first product, Neutrocheck®, a portable finger-prick blood test and app to identify immunosuppressed patients at risk of neutropenic sepsis, was awarded breakthrough status by the UK Government in 2024. Their product portfolio also includes ACORN™, a digital tool for remote triaging and management of emergency cancer care needs, and Aster™, the world’s first portable platform for cell measurement.
Team and Leadership
The leadership includes Umaima Ahmad, CEO and Founder; Dr Rebecca Simmons, COO; Dr Mireia Crispin, Chief Digital Officer; Dr Saif Ahmad, Chief Scientific & Medical Officer; and Joe Neale, CTO. The team comprises experts in science, engineering, clinical practice, and business, dedicated to developing impactful medical technologies.